Anticoagulant therapy with a selective XXXX inhibitor for acute @entity385 : usefulness of coagulation markers for evaluation of efficacy.

@entity1 @entity64 @entity556 @entity20806 @entity49 @entity1188 @entity385
BACKGROUND: @entity20806 is a selective @entity556 inhibitor used for the treatment of @entity1188 . We evaluated its therapeutic effect using coagulation markers in 30 @entity1 with @entity1188 and 30 @entity1 with @entity1188 during the immediate period after @entity385 . METHODS: Argatroban therapy was initiated within 24 hours of the onset of @entity64 and the course was followed until 7 days after the start of treatment. Neurological evaluation was performed using the @entity64 ( @entity64 ). We also monitored the serial changes in activated partial thromboplastin time, prothrombin time, @entity556 -antithrombin complex (TAT), and prothrombin fragments 1 + 2 (F1 + 2). RESULTS: Both groups of @entity1 showed significant improvement of @entity64 after 7 days of argatroban therapy (p < 0.05). @entity385 developed in 8 of @entity1 with @entity1188 , but no worsening of symptoms was noted in any of these @entity1 . There was no significant prolongation of activated partial thromboplastin time or prothrombin time after 7 days, while levels of both TAT and F1 + 2 were significantly decreased from day 2. CONCLUSION: The decrease in TAT and F1 + 2 during argatroban therapy suggested improvement of @entity49 , which might explain how this drug prevents the recurrence of both ATI and CEI in the acute stage. Our findings also suggested that TAT and F1 + 2 might be useful indices for evaluation of argatroban efficacy.
